Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

  • Revenue in CHF (TTM)5.85bn
  • Net income in CHF909.00m
  • Incorporated2002
  • Employees17.15k
  • Location
    Lonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
  • Phone+41 613168111
  • Fax+41 613169111
  • Websitehttps://www.lonza.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LONN:SWX since
Codiak BioSciences Inc-Exosomes Manufacturing Facility,Lexington,MAAnnounced02 Nov 202102 Nov 2021Announced-26.02%--
Data delayed at least 15 minutes, as of Aug 08 2022 12:17 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Qiagen NV2.17bn494.49m10.88bn6.00k22.253.4415.675.,421.508.533.699.714.2864.4465.5422.7511.681.89181.360.3709--20.3910.9742.7144.8417.07--
Vifor Pharma AG1.75bn146.60m11.14bn2.30k76.113.1923.686.352.252.2226.9853.780.34031.963.78762,695.605.154.776.756.3061.7059.8115.1313.941.56--0.132102.792.858.495.70-0.0681-2.520.00
Croda International Plc2.42bn825.02m11.48bn6.14k13.944.1911.864.755.085.0814.8916.910.56862.714.97339,511.0019.5211.1722.6313.1648.2243.7134.3316.392.2524.360.320261.7835.918.7359.1310.288.535.70
BioMerieux SA3.30bn588.41m12.48bn13.08k21.064.0415.133.785.065.0628.4226.400.79032.405.68258,198.2014.029.7818.2513.1358.1655.4717.7412.691.6467.030.127214.148.279.9348.6427.404.4820.59
UCB SA5.80bn868.28m14.04bn8.56k16.161.5710.942.424.564.5630.4746.940.40371.824.79691,975.306.057.397.389.3073.0974.3414.9916.730.82836.690.252828.568.046.8544.1314.2129.002.48
Eurofins Scientific SE6.71bn806.31m14.16bn61.00k18.253.0810.,238.709.057.6611.399.7325.1323.5212.4911.801.2510.160.412416.2223.5121.5050.0739.8821.0737.97
argenx SE120.65m-872.42m19.53bn650.00--6.84--161.89-17.00-17.002.3052.990.03880.06552.02189,621.30-28.08-20.19-30.48-22.8673.49---723.09-191.4310.56-8.940.0033--1,105.7398.1632.90--163.70--
Lonza Group AG5.85bn909.00m41.72bn17.15k45.884.1528.997.1312.2141.8778.57134.940.3667----360,648.705.725.007.016.1438.6939.8215.5913.97--12.820.192431.4019.995.53-7.6717.4929.663.33
GSK plc37.98bn4.56bn78.69bn90.10k15.173.319.,201.505.806.9610.2011.6165.4068.4814.7114.681.3110.400.494194.850.0444.11-23.7336.904.50-4.36
Sanofi SA41.15bn6.49bn120.98bn95.44k18.501.7214.782.945.275.2733.5056.670.35911.385.73440,466.505.685.196.916.2369.4568.0615.8215.360.86132.430.231166.944.832.46-49.387.20-0.3872.28
Novo Nordisk A/S20.68bn6.65bn173.27bn50.82k34.3022.8123.308.3822.0422.0468.5433.150.83421.254.703,290,321.0026.8132.6551.9563.1283.9283.7932.1433.520.741219.080.254650.1810.914.7213.334.72-2.236.47
AstraZeneca plc42.34bn-1.20bn196.79bn83.10k--5.7032.004.65-0.7043-0.704323.6619.210.51742.025.77439,018.10-1.472.62-1.983.6674.8578.90-2.846.610.67375.850.451196.2640.5810.22-96.50-49.76-1.011.03
Data as of Aug 08 2022. Currency figures normalised to Lonza Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

19.12%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Jul 20222.39m3.21%
The Vanguard Group, Inc.as of 08 Jul 20221.92m2.58%
Norges Bank Investment Managementas of 31 Dec 20211.78m2.39%
Fidelity Management & Research Co. LLCas of 31 May 20221.69m2.27%
UBS Asset Management Switzerland AGas of 05 Jul 20221.41m1.90%
Capital Research & Management Co. (World Investors)as of 30 Jun 20221.29m1.73%
BlackRock Fund Advisorsas of 07 Jul 20221.19m1.60%
WCM Investment Management LLCas of 31 May 2022957.63k1.29%
Credit Suisse Asset Management (Schweiz) AGas of 29 Jul 2022835.34k1.12%
Z�rcher Kantonalbank (Investment Management)as of 31 Mar 2022767.22k1.03%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.